Cure My Disease

Don't miss your cure!

 Log in / Sign up

Ultra-Fast CAR-T cells aim to beat back tough lymphomas

NCT ID NCT07713459

Not yet recruiting ⭐️ CURE ⭐️ Sponsor: Kure Cells, INC Source: ClinicalTrials.gov ↗

First seen Jul 20, 2026 · Last updated Jul 21, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether a new CAR-T cell therapy called UF-KURE19 can effectively treat adults with relapsed or refractory B-cell non-Hodgkin lymphomas, including large B-cell lymphoma, follicular lymphoma, and marginal zone lymphoma. The therapy is made from a patient's own immune cells in less than one day. Participants receive a single infusion of these engineered cells, and researchers track how many achieve a complete response by day 90.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
a fast-made CAR-T cell therapy called UF-KURE19, targeting CD19 on cancer cells
What this could lead to
If successful, this could offer a durable, one-time treatment option for people with hard-to-treat B-cell lymphomas, potentially leading to long-term remission without further therapy.
What could go wrong
This is a single-arm phase 2 trial with no comparison group, so results may be less definitive. CAR-T therapies carry risks of severe side effects like cytokine release syndrome and neurological toxicity.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CAR T CELL THERAPY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diffuse large B-cell lymphoma follicular lymphoma high grade B-cell lymphoma Lymphoma, B-Cell, Marginal Zone marginal zone lymphoma non-Hodgkin lymphoma primary mediastinal large B-cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CAR T CELL THERAPY DIFFUSE LARGE B CELL LYMPHOMA (DLBCL) FOLLICULAR B-CELL NON-HODGKIN'S LYMPHOMA LYMPHOMA NONHODGKIN MARGINAL ZONE B CELL LYMPHOMA

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.